• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于人群的研究:开发和验证用于预测膀胱癌患者根治性膀胱切除术后癌症特异性生存的预后列线图。

Development and validation of a prognostic nomogram for predicting cancer-specific survival after radical cystectomy in patients with bladder cancer:A population-based study.

机构信息

Department of Urology, West China Hospital, Sichuan University, Chengdu, People's Republic of China.

West China School of Medicine/West China Hospital, Sichuan University, Chengdu, People's Republic of China.

出版信息

Cancer Med. 2020 Dec;9(24):9303-9314. doi: 10.1002/cam4.3535. Epub 2020 Oct 16.

DOI:10.1002/cam4.3535
PMID:33063464
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7774742/
Abstract

PURPOSE

To establish a prognostic model to estimate the cancer-specific survival (CSS) for urothelial carcinoma of bladder (UCB) patients after radical cystectomy (RC).

METHODS

A total of 8650 candidates (2004-2011) obtained from the Surveillance, Epidemiology, and End Results (SEER) database were randomly split into development cohort (n = 4323) and validation cohort (n = 4327). We performed Cox regression analysis to identify prognostic factors and Kaplan-Meier analysis to assess survival outcome. A nomogram predicting CSS was constructed. Its performance was validated by calibration curves, the receiver operating characteristic (ROC) curves, concordance index (C-index), decision curve analysis (DCA), the net reclassification improvement (NRI), and the integrated discrimination improvement (IDI).

RESULTS

The nomogram incorporated marital status, T stage, N stage, tumor size, and chemotherapy. In validation cohort, C-index of the nomogram was 0.707. AUC of the nomogram and AJCC stage were 0.767 versus 0.674. Calibration plots for 3- and 5-year CSS displayed good concordance. DCA curves of the nomogram exhibited larger benefits than the AJCC stage. The NRI and IDI indicated the nomogram outperformed AJCC stage.

CONCLUSIONS

We have established a prognostic nomogram with improved discriminative ability and clinical benefits for UCB patients after RC. The nomogram alongside an easy access web tool may assist clinicians in optimizing the postoperative management.

摘要

目的

建立一个预后模型,以估计根治性膀胱切除术 (RC) 后膀胱癌 (UCB) 患者的癌症特异性生存 (CSS)。

方法

从监测、流行病学和最终结果 (SEER) 数据库中随机抽取 8650 名候选人(2004-2011 年),分为开发队列 (n=4323) 和验证队列 (n=4327)。我们进行 Cox 回归分析以确定预后因素,并进行 Kaplan-Meier 分析以评估生存结果。构建了一个预测 CSS 的列线图。通过校准曲线、接收者操作特征 (ROC) 曲线、一致性指数 (C-index)、决策曲线分析 (DCA)、净重新分类改善 (NRI) 和综合判别改善 (IDI) 验证了其性能。

结果

该列线图纳入了婚姻状况、T 分期、N 分期、肿瘤大小和化疗。在验证队列中,列线图的 C-index 为 0.707。列线图和 AJCC 分期的 AUC 分别为 0.767 与 0.674。3 年和 5 年 CSS 的校准图显示出良好的一致性。DCA 曲线表明列线图的获益大于 AJCC 分期。NRI 和 IDI 表明列线图优于 AJCC 分期。

结论

我们建立了一个具有更好鉴别能力和临床获益的 RC 后 UCB 患者预后列线图。该列线图和一个易于访问的网络工具可以帮助临床医生优化术后管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b69/7774742/839c708d93b7/CAM4-9-9303-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b69/7774742/607c2dc2a6fb/CAM4-9-9303-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b69/7774742/737f33c00c4e/CAM4-9-9303-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b69/7774742/839c708d93b7/CAM4-9-9303-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b69/7774742/607c2dc2a6fb/CAM4-9-9303-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b69/7774742/737f33c00c4e/CAM4-9-9303-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b69/7774742/839c708d93b7/CAM4-9-9303-g004.jpg

相似文献

1
Development and validation of a prognostic nomogram for predicting cancer-specific survival after radical cystectomy in patients with bladder cancer:A population-based study.基于人群的研究:开发和验证用于预测膀胱癌患者根治性膀胱切除术后癌症特异性生存的预后列线图。
Cancer Med. 2020 Dec;9(24):9303-9314. doi: 10.1002/cam4.3535. Epub 2020 Oct 16.
2
Development and validation of a prognostic nomogram for predicting overall survival in patients with primary bladder sarcoma: a SEER-based retrospective study.基于 SEER 的回顾性研究:开发和验证用于预测原发性膀胱肉瘤患者总生存期的预后列线图。
BMC Urol. 2021 Nov 25;21(1):162. doi: 10.1186/s12894-021-00929-x.
3
A prognostic nomogram for the cancer-specific survival of patients with upper-tract urothelial carcinoma based on the Surveillance, Epidemiology, and End Results Database.基于监测、流行病学和最终结果数据库的上尿路上皮癌患者癌症特异性生存的预后列线图。
BMC Cancer. 2020 Jun 8;20(1):534. doi: 10.1186/s12885-020-07019-5.
4
Development and validation of a nomogram for predicting cancer-specific survival in small-bowel adenocarcinoma patients using the SEER database.基于 SEER 数据库的列线图模型构建与验证:用于预测小肠腺癌患者癌症特异性生存的研究。
World J Surg Oncol. 2024 Jun 7;22(1):151. doi: 10.1186/s12957-024-03438-x.
5
Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making.pT4a期膀胱尿路上皮癌根治性膀胱切除术后癌症特异性生存的预测:一种临床决策工具的开发
BJU Int. 2016 Feb;117(2):272-9. doi: 10.1111/bju.12984. Epub 2015 May 24.
6
The Cancer of the Bladder Risk Assessment (COBRA) score for predicting cancer-specific survival after radical cystectomy for urothelial carcinoma of the bladder: External validation in a cohort of Korean patients.膀胱癌风险评估(COBRA)评分预测膀胱癌根治性膀胱切除术后癌症特异性生存:韩国患者队列的外部验证。
Urol Oncol. 2019 Jul;37(7):470-477. doi: 10.1016/j.urolonc.2019.03.006. Epub 2019 Mar 29.
7
A convenient clinical nomogram for predicting the cancer-specific survival of individual patients with small-intestine adenocarcinoma.用于预测个体小肠腺癌患者癌症特异性生存的便捷临床列线图。
BMC Cancer. 2020 Jun 1;20(1):505. doi: 10.1186/s12885-020-06971-6.
8
Two web-based dynamically interactive nomograms and risk stratification systems for predicting survival outcomes and guiding treatment in non-metastatic nasopharyngeal carcinoma.用于预测非转移性鼻咽癌生存结局并指导治疗的两个基于网络的动态交互式列线图和风险分层系统。
J Cancer Res Clin Oncol. 2023 Nov;149(17):15969-15987. doi: 10.1007/s00432-023-05363-0. Epub 2023 Sep 8.
9
Development and validation of competing risk nomograms for predicting cancer‑specific mortality in non-metastatic patients with non‑muscle invasive urothelial bladder cancer.开发和验证列线图模型预测非转移性非肌肉浸润性膀胱癌患者的癌症特异性死亡率的竞争风险。
Sci Rep. 2024 Jul 31;14(1):17641. doi: 10.1038/s41598-024-68474-9.
10
Bladder cancer survival nomogram: Development and validation of a prediction tool, using the SEER and TCGA databases.膀胱癌生存列线图:利用监测、流行病学和最终结果(SEER)数据库及癌症基因组图谱(TCGA)数据库开发并验证一种预测工具
Medicine (Baltimore). 2019 Nov;98(44):e17725. doi: 10.1097/MD.0000000000017725.

引用本文的文献

1
Using machine learning for predicting cancer-specific mortality in bladder cancer patients undergoing radical cystectomy: a SEER-based study.使用机器学习预测接受根治性膀胱切除术的膀胱癌患者的癌症特异性死亡率:一项基于监测、流行病学和最终结果(SEER)数据库的研究
BMC Cancer. 2025 Mar 21;25(1):523. doi: 10.1186/s12885-025-13942-2.
2
Development and Validation of a Competitive Risk Model in Elderly Patients with Transitional Cell Bladder Carcinoma.老年移行细胞膀胱癌患者竞争风险模型的建立与验证
Med Sci Monit. 2025 Jan 29;31:e946332. doi: 10.12659/MSM.946332.
3
Nomogram for predicting all-cause mortality and cancer-specific mortality after TURBT for non-muscle-invasive bladder cancer.

本文引用的文献

1
Staging of bladder cancer.膀胱癌分期。
Histopathology. 2019 Jan;74(1):112-134. doi: 10.1111/his.13734.
2
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
3
Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy.BCG 治疗后行根治性膀胱切除术的 T1G3 患者的肿瘤学结局预测因素。
膀胱癌经 TURBT 治疗后的全因死亡率和癌症特异性死亡率预测列线图。
Sci Rep. 2024 Nov 20;14(1):28759. doi: 10.1038/s41598-024-80333-1.
4
A Novel Decision Tree Model for Predicting the Cancer-Specific Survival of Patients with Bladder Cancer Treated with Radical Cystectomy.一种用于预测接受根治性膀胱切除术治疗的膀胱癌患者癌症特异性生存率的新型决策树模型。
J Clin Med. 2024 Apr 10;13(8):2177. doi: 10.3390/jcm13082177.
5
Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer.评估前列腺尿道受累对 T1 期膀胱癌预后的影响并建立列线图。
BMC Urol. 2023 Nov 10;23(1):182. doi: 10.1186/s12894-023-01342-2.
6
Development and validation a model for predicting overall survival of bladder cancer with lung metastasis: a population-based study.建立和验证一个用于预测膀胱癌伴肺转移患者总生存期的模型:一项基于人群的研究。
Eur J Med Res. 2023 Aug 10;28(1):279. doi: 10.1186/s40001-023-01261-w.
7
Survival nomogram for high-grade bladder cancer patients after surgery based on the SEER database and external validation cohort.基于监测、流行病学和最终结果(SEER)数据库及外部验证队列的高级别膀胱癌患者术后生存列线图。
Front Oncol. 2023 Jun 16;13:1164401. doi: 10.3389/fonc.2023.1164401. eCollection 2023.
8
Surveillance of prognostic risk factors in patients with SCCB using artificial intelligence: a retrospective study.利用人工智能监测 SCCB 患者的预后风险因素:一项回顾性研究。
Sci Rep. 2023 May 30;13(1):8727. doi: 10.1038/s41598-023-35761-w.
9
A Prognostic Nomogram Based on Log Odds of Positive Lymph Nodes to Predict Overall Survival for Non-Metastatic Bladder Cancer Patients after Radical Cystectomy.基于阳性淋巴结对数优势的预后列线图预测根治性膀胱切除术后非转移性膀胱癌患者的总生存。
Curr Oncol. 2022 Sep 23;29(10):6834-6846. doi: 10.3390/curroncol29100539.
10
Competitive Risk Model for Specific Mortality Prediction in Patients with Bladder Cancer: A Population-Based Cohort Study with Machine Learning.膀胱癌患者特定死亡率预测的竞争风险模型:一项基于人群队列的机器学习研究
J Oncol. 2022 Aug 25;2022:9577904. doi: 10.1155/2022/9577904. eCollection 2022.
World J Urol. 2018 Nov;36(11):1775-1781. doi: 10.1007/s00345-018-2450-0. Epub 2018 Aug 31.
4
Pelvic lymph node dissection during radical cystectomy for muscle-invasive bladder cancer.根治性膀胱切除术治疗肌层浸润性膀胱癌时的盆腔淋巴结清扫术。
Nat Rev Urol. 2018 Nov;15(11):686-692. doi: 10.1038/s41585-018-0066-1.
5
The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy.膀胱癌风险评估(COBRA)评分:评估根治性膀胱切除术后的死亡率。
Cancer. 2017 Dec 1;123(23):4574-4582. doi: 10.1002/cncr.30918. Epub 2017 Sep 7.
6
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.2016 年更新版 EAU 肌层浸润性和转移性膀胱癌临床实践指南。
Eur Urol. 2017 Mar;71(3):462-475. doi: 10.1016/j.eururo.2016.06.020. Epub 2016 Jun 30.
7
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.EAU 指南:非肌层浸润性膀胱尿路上皮癌:2016 年更新版。
Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.
8
External Validation of Bladder Cancer Predictive Nomograms for Recurrence, Cancer-Free Survival and Overall Survival following Radical Cystectomy.根治性膀胱切除术后膀胱癌复发、无癌生存和总生存预测列线图的外部验证
J Urol. 2016 Feb;195(2):283-9. doi: 10.1016/j.juro.2015.08.093. Epub 2015 Sep 5.
9
Decreased Overall and Bladder Cancer-Specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis.根治性膀胱切除术辅助化疗降低总体和膀胱癌特异性死亡率:多变量竞争风险分析。
Eur Urol. 2016 Jun;69(6):984-7. doi: 10.1016/j.eururo.2015.06.053. Epub 2015 Jul 17.
10
Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy.预测根治性膀胱切除术后无病生存期和癌症特异性生存期列线图的开发与外部验证
World J Urol. 2015 Oct;33(10):1419-28. doi: 10.1007/s00345-014-1465-4. Epub 2014 Dec 27.